Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609320 | 1.00 | VCAM1 (0.46) | VCAM1TXNRD1MAPTMERTKGSR | |
| SCHEMBL13731937 | 0.81 | CTSB (0.42) | VCAM1MAPTTDP1POLBL3MBTL1 | |
| SCHEMBL21816202 | 0.78 | CTSB (0.49) | VCAM1MAPTTDP1POLBCTSB | |
| SCHEMBL6837266 | 0.78 | CTSB (0.42) | VCAM1MAPTTDP1POLBCTSB | |
| SCHEMBL56616 | 0.76 | MAPT (0.50) | TXNRD1MAPTMERTKGSRTDP1 | |
| SCHEMBL29364858 | 0.76 | MAPT (0.50) | TXNRD1MAPTMERTKGSRTDP1 | |
| SCHEMBL8657532 | 0.76 | ALDH1A1 (0.46) | VCAM1TXNRD1MAPTMERTKGSR | |
| SCHEMBL30271385 | 0.75 | MAPT (0.53) | TXNRD1MAPTMERTKGSRTDP1 | |
| SCHEMBL8710611 | 0.75 | MAPT (0.53) | TXNRD1MAPTMERTKGSRTDP1 | |
| SCHEMBL17434625 | 0.75 | MAPT (0.49) | TXNRD1MAPTMERTKGSRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4631948-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4587124-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | Enliven Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| CN-119546604-A | Pyrido [3,2-D ] pyrimidines as HPK1 inhibitors | 默克专利有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4476211-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024123102-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | 에스케이바이오팜 주식회사 | 2024-06-13 | — | — | WO | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| WO-2000066592-A1 | CYCLIC UREA AND CYCLIC AMIDE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| CN-1139383-A | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| US-5330987-A | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists | MERCK & CO., INC. (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0272533-A2 | Substituted phenoxypyridines | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | VCAM1 4683/4885TXNRD1 1290/4885MAPT 3827/4885 |
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, PPIP5K2, IP6K1 | VCAM1 3489/4885TXNRD1 2701/4885MAPT 3349/4885 |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | VCAM1 3874/4885TXNRD1 2722/4885MAPT 4560/4885 |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | VCAM1 3223/4885TXNRD1 1305/4885MAPT 222/4885 |
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ERBB2, BRCA1, ERBB3 | VCAM1 3940/4885TXNRD1 1224/4885MAPT 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.